| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69f4a8023526eebfdf4b51f9a4c75c9e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59b650894165d72218a0766f7a83f124
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e147579187072f52ecce6141da00c5fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9907c158bc927e75e37b0985576e0f93
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a9d4070858cbe71370f2f5f5c4fd2e84 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-642
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-48269
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-19 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate |
2012-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca7922a20c21b18e0d219852a042f821
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5b52d6c1b13df8791d5589edc454b82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a962f0bda3ee57aebb1b519e0d143380
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d78dcd63c47e4df9c09cb1249aece132 |
| publicationDate |
2017-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9642917-B2 |
| titleOfInvention |
Use of G-CSF dimer in preparation of medicament for treatment of neurodegenerative diseases |
| abstract |
The invention discloses the use of the G-CSF dimer in the preparation of a medicament for the treatment of neurodegenerative diseases. Use of the G-CSF dimer of the present invention can significantly increase the number of dopaminergic neuron in the substantia nigra in PD model animals and enhance the function of dopaminergic neurons. In addition, the G-CSF dimer can significantly reduce apoptosis of neuron in hippocampus and improve learning and memory ability of AD model rats. Serum half-life of the G-CSF dimer of the invention is prolonged and the loss of neurons is effectively prevented, providing a better therapeutic effect in treatment of neurodegenerative disease. |
| priorityDate |
2011-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |